Our findings highlight that the RMS was a potent predictor to assess the clinical outcome of distinct immunotherapy regimens (anti-PD1/L1 or anti-MAGE-3), which was validated in two UC immunotherapy cohort and two melanoma immunotherapy cohorts. Here, MAGEA3 is linked to melanoma.